News
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
European Commission Expands Approval of Sobi’s Aspaveli® for Rare Kidney Diseases
Aspaveli ® is also approved for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH) in the United States, European Union, and other countries globally.
GEMMA Biotherapeutic Announces Clinical Trial Authorization for New Gene Therapy Treatment
GEMMA announced that its novel gene therapy for spinal muscular atrophy type 1 (SMA1) has been cleared for clinical trial in Brazil.
Solid Biosciences Doses First Participant in First-in-Class Clinical Trial Evaluating Gene Therapy for the Treatment of Friedreich’s Ataxia
Initial trial data is expected in the second half of 2026.
Osetomics Appoints Global Medical Device Leader as CEO
The company is currently raising $8.5 million to support further development of its diagnostic and prognostic tools.
Vasowatch Receives $150K from Ben Franklin University Partners
Vasowatch received $150K from Ben Franklin Technology Partners.
Linnaeus Therapeutics Awarded Up to $22 Million from ARPA-H to Advance its Lead Drug Candidate for Healthspan Preservation
Linnaeus will use these funds to further develop LNS880.
PCI Showcases Precision Medicine During the JP Morgan Healthcare Conference
PCI hosted its annual Innovation @ Penn program at Wharton San Francisco.
Penn, BioNTech SE and Osage University Partners (OUP) Launch $50 Million Penn-BioNTech Innovative Therapeutics Seed Fund
The dedicated venture capital fund will invest in early-stage life science companies spun out of Penn.
Penn I-Corps Fall 2025 Cohort Completes Program
Ten teams completed the program, and 26 individuals received valuable training in entrepreneurship.
Washington Post Article Highlights Bayh-Dole’s Role in U.S. Innovation
The article discusses how nearly all significant modern medicines originated from taxpayer-funded university research.